In vivo electrochemical measurement of the long-lasting release of dopamine and serotonin induced by intrastriatal kainic acid

Effect of thiamazole on kainic acid-induced seizures in mice

Kainic acid (KA) induced epileptic seizures in mice is a commonly used experimental model of epilepsy. Previous studies have suggested the roles of various neurotransmitters and oxidative stress in KA-induced seizures. An important role of hypothyroidism has also been suggested in epilepsy. Thiamazole (TZ) is an anti-hyperthyroid drug with antioxidant property. This study reports the effect of TZ on KA-induced epileptic seizures in mice, produced by intraperitoneal (IP) injection of KA (18 mg/kg). Prior to KA injection, the animals were treated with TZ (12.5, 25 and 50 mg/kg IP). Our results showed that in KA alone group, about half of the animals developed seizures. Pre-treatment of mice with TZ significantly increased the frequency of seizures in dose-dependent manner. Administration of TZ significantly reduced the latency time and aggravated the severity of seizures. TZ also increased the mortality in KA-treated mice. Striatal dopamine and serotonin levels were markedly increased in KA alone treated mice, which were not significantly affected by TZ treatment. Among the indices of oxidative stress, we observed a significant reduction in cerebral vitamin E whereas the levels of cerebral malondialdehyde and conjugated dienes were significantly increased in animals with high severity of seizures. In conclusion, TZ potentiated the frequency and severity of experimental seizure in mice. There is a possibility of altered metabolism of KA in presence of TZ that might have potentiated the toxicity of KA. These findings suggest a caution while administering anti-hyperthyroid drugs in epileptic seizures.

A microsensing system for the in vivo real-time detection of local drug kinetics

Real-time recording of the kinetics of systemically administered drugs in in vivo microenvironments may accelerate the development of effective medical therapies. However, conventional methods require considerable analyte quantities, have low sampling rates and do not address how drug kinetics correlate with target function over time. Here, we describe the development and application of a drug-sensing system consisting of a glass microelectrode and a microsensor composed of boron-doped diamond with a tip of around 40 μm in diameter. We show that, in the guinea pig cochlea, the system can measure-simultaneously and in real time-changes in the concentration of bumetanide (a diuretic that is ototoxic but applicable to epilepsy treatment) and the endocochlear potential underlying hearing. In the rat brain, we tracked the kinetics of the drug and the local field potentials representing neuronal activity. We also show that the actions of the antiepileptic drug lamotrigine and the anticancer reagent doxorubicin can be monitored in vivo. Our microsensing system offers the potential to detect pharmacological and physiological responses that might otherwise remain undetected.

Wireless voltammetry recording in unanesthetised behaving rats

In vivo voltammetry is a valuable technique for rapid measurement of dopamine in the brain of freely behaving rats. Using a conventional voltammetry system, however, behavioural freedom is restricted by cables connecting the head assembly to the measurement system. To overcome these difficulties, we developed a wireless voltammetry system utilizing radio waves. This system consisted of a potentiostat and transmitter system that was mounted on the back of the rat, and a receiver and analysis system. A single-step pulse (100-250 mV) was applied at 4 Hz after an activation pulse to a carbon fibre recording electrode (diameter: 7 microm). Measurement of dopamine (detection limit: 2.7 x 10(-7)M) was demonstrated in vitro. In vivo experiment was performed at least 1 week after the recording electrode was implanted in the rat striatum. Administration of 2-phenylethylamine to rats increased dopamine signal current, which was consistent with the result in the microdialysis measurement. During a resident-intruder test, dopamine signal current in a resident rat increased upon introduction of an intruder rat. These results show that the present wireless system is useful for a long-term measurement of dopamine in behaving rats.

Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease

L-3,4-Dihydroxyphenylalanine (L-DOPA) is a common and effective treatment for Parkinson's disease, but dyskinesia continues to be a serious adverse effect with chronic use. Evidence suggests that L-DOPA induces increases in dopamine, which then binds to supersensitive dopamine receptors, resulting in dyskinesia. We have shown previously that L-DOPA directly causes stereotypy in rats, suggesting that chronic L-DOPA-induced dyskinesia is also caused by L-DOPA itself. This raises the possibility that other L-DOPA metabolites have a role in dyskinesia. We examined the behavioral effects of five L-DOPA metabolites (3-methoxytyramine, 3-MT; 3,4-dihydroxyphenylalanine, DOPAC; dopamine; homovanillic acid, and 3-o-methyl-DOPA) in rats. A unilateral, intracerebroventricular injection of 3-MT (10-200 microg, 40 microl) over 30 min, dose-dependently increased behavioral activity and stereotypy. This effect was suppressed by the dopamine D1/5-receptor antagonist SCH 23390, but not by the dopamine D2/3/4-receptor antagonist sulpiride. Dopamine denervation resulted in behavioral supersensitivity to 3-MT. Neither dopamine nor DOPAC levels increased in the striatum after 3-MT administration, as measured using in vivo voltammetry. The behavioral changes paralleled a rise in 3-MT in the contralateral striatum. DOPAC also caused behavioral changes and stereotypy, but to a smaller degree than 3-MT. Dopamine-denervated rats did not exhibit a supersensitive response to DOPAC, however. Other L-DOPA metabolites did not cause behavioral effects. These data suggest that 3-MT directly induced dopamine-D1/5-receptor-mediated behavioral changes in rats, and that 3-MT may have a role in dyskinesia due to chronic L-DOPA treatment in Parkinson's disease patients.

Comparative study of hippocampal neuronal loss and in vivo binding of 5-HT1a receptors in the KA model of limbic epilepsy in the rat

A high density of 5-HT1a receptors is present in pyramidal hippocampal cells. Mapping of these receptors may be performed in vivo using the tracer no-carrier-added 4-(18)F-fluoro-N-2-(1-(2-methoxyphenyl)-1-piperazinyl)ethyl-N-2-pyridinyl-benzamide (MPPF). We tested the hypothesis of a relationship between MPPF binding and post-epileptic neuronal loss in the hippocampus. The model of limbic epilepsy induced by kainic acid (KA) in the rat was used. Rats were sacrificed at various times (1 h-240 days) after systemic injection of 10 mg/kg KA. Determination of MPPF binding in the brain was combined with a quantification of neuronal loss using DNA labeling with propidium iodide and confocal microscopy. Hippocampal MPPF binding varied according to time elapsed from KA injection. An initial decrease from day 1 to day 6 post injection was followed by a relative increase between day 6 and day 30. This effect was observed in rats which showed hippocampal neuronal loss but also in one rat which did not. In KA treated rats, statistically significant relationship between MPPF binding and neuronal count was found during the acute period (rats sacrificed 1 h-day 6 after KA injection) and the chronic phase (rats sacrificed beyond day 60 after KA injection). The late relative increase of MPPF binding suggests an epilepsy-induced increase of 5-HT1a receptors in the hippocampus. This effect needs to be further characterized before considering PET determination of hippocampal MPPF binding as a method of post-epileptic neuronal loss assessment.

High-speed voltammetry: dual measurement of dopamine and serotonin

A high-speed voltammetric system was designed and tested for dual measurement of dopamine (DA) and serotonin (5-HT) at 250-ms intervals. First, an anodic-cathodic square-wave pulse was delivered to activate the electrode (carbon fiber, 7 microm in diameter), then DA and 5-HT oxidation currents (current intensity) were measured when potentials were stepped from 100 to 250 mV and 300 to 450 mV, respectively. To isolate DA and 5-HT current intensities, the current observed at 100 mV was subtracted from that at 250 mV, and the current observed at 300 mV was subtracted from that at 450 mV, respectively. Measurements were performed every 250 ms. In vitro, DA and 5-HT current intensities increased with increasing concentrations of DA and 5-HT, respectively. The DA current intensity was not affected by the addition of the DA metabolite 3,4-dihydroxyphenylacetic acid (10(-6) M) or ascorbic acid (10(-5) M), but the 5-HT current intensity was affected by the addition of the 5-HT metabolite 5-hydroxyindoleacetic acid (10(-6) M) or uric acid (10(-5) M). Electrodes were used for several months without any change in sensitivity. In vivo, following intraperitoneal injection of L-DOPA to rats, an increase in striatal DA release was observed but there was no increase in release of 5-HT. Following intraperitoneal injection of 5-hydroxytryptamine there was an increase in 5-HT release but not DA release. This high-speed system was capable of obtaining stable, long-term dual measurements of DA and 5-HT in vitro and in vivo.